N@N

NBIX, FORM, CROX, HWCC, OSIR, URZ Expected to Trade Up After Bullish Patterns Develop

April 20, 2011 / M2 PRESSWIRE / BUYINS.NET / http://www.squeezetrigger.com is monitoring top technical trading patterns and these stocks are the most likely to trade Up in the coming weeks. NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX), FORMFACTOR INC (NASDAQ:FORM), CROCS INC (NASDAQ:CROX), HOUSTON WIRE & CABLE CO (NASDAQ:HWCC), OSIRIS THERAPEUTICS INC (NASDAQ:OSIR), URANERZ ENERGY CORP (AMEX:URZ) are all expected to go Up as Bullish signals have been generated by top technical trading patterns. We monitor these patterns: Support Break, Support Reversal, Breakaway Gap, Measured Gap, Exhaustion Gap, Resistance Break, Resistance Reversal, Saucer Reversal, Volume Climax, Volume Trend, Fibonacci Reversal, Consolidation Breaks, Trend Line Break,Trend Line Reversal, Candles, Golden Crosses, Death Crosses and more. The chart below displays the stocks expected to go Up along with pattern, strategy and strength ratings.

     Symbol     Company                             Strategy                            Pattern Name            Strength  
     NBIX       NEUROCRINE BIOSCIENCES INC          Breakout (Stocks) DO                Triangle, Symmetrical     3         
     FORM       FORMFACTOR INC                      Breakout (Stocks) DO                62 % Retracement        1         
     CROX       CROCS INC                           Breakout (Stocks) DO                Broadening Continuation     1         
     HWCC       HOUSTON WIRE & CABLE CO             Trending (Stocks) DO                Broadening Continuation     1         
     OSIR       OSIRIS THERAPEUTICS INC             Reversal (Stocks) DWC               Broadening Top          4         
     URZ        URANERZ ENERGY CORP                 Reversal (Stocks) DWC               Trend Line Reversal(3)     1         

Chart Pattern Recognition is based on a 20-year patterns database. This database is used to determine pattern strength for patterns as they appear. There is no optimization and the pattern signals never change. For each pattern variation, we record accuracy and profitability statistics in a patterns database. From this information, we are able to define strength ratings from 1 to 5. The '1' rating shows ALL patterns while a '5' rating shows the best patterns according to profitability. Each pattern has its own strength rating factors. The result is an automatic ranking system that allows us to only show the BEST patterns. You can see that, at Strength 5, virtually all the patterns are profitable. The pattern strength rating system separates the most profitable patterns. The specific technology used to make these predictions is available for a low monthly fee at: http://www.squeezetrigger.com/services/sw/ot.php

NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) - Neurocrine Biosciences, Inc. engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. It develops drugs for endometriosis, anxiety, depression, pain, diabetes, irritable bowel syndrome, insomnia, and other neurological and endocrine-related diseases and disorders. Its products in clinical development include Elagolix, a phase II product for endometriosis; CRF1 Antagonist, a phase II product for mood disorders; CRF2 Peptide Agonist, a phase II drug for cardiovascular diseases; CRF1 Antagonist, a phase I product for treating mood disorders and irritable bowel syndrome; Vesicular Monoamine Transporter 2 Inhibitor, a phase I product for movement disorders and schizophrenia; and Elagolix, a phase I product for uterine fibroids, and mens and womens health. The companys research programs comprise Glucose Dependent Insulin Secretagogues for type II diabetes; Antiepileptic Drugs for epilepsy and bipolar disorder; and GnRH Antagonists for hormone dependent diseases and oncology. Its product pipeline also includes Indiplon 5mg and 10mg capsules, the FDA deemed approvable products, for the treatment of insomnia. The company has collaborations with GlaxoSmithKline to develop and commercialize CRF antagonists for psychiatric, neurological, and gastrointestinal diseases; Dainippon Sumitomo Pharma Co. Ltd. to develop and commercialize Indiplon in Japan; Abbott Laboratories to develop and commercialize elagolix for the treatment of endometriosis-related pain; and Boehringer Ingelheim to research and develop small molecule GPR119 agonists for the treatment of Type II diabetes and other indications. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.

FORMFACTOR INC (NASDAQ:FORM) - FormFactor, Inc. engages in the design, development, manufacture, sale, and support of semiconductor wafer probe card products and solutions based on MicroSpring interconnect technology. Its wafer probe cards are used by semiconductor manufacturers to perform wafer sort and test on the semiconductor die, chips, or the whole semiconductor wafer in the front end of the semiconductor manufacturing process. The companys customers use its wafer probe cards to test DRAM chips, including DDR, DDR2, DDR3, SDRAM, PSRAM, mobile DRAM, Graphic DRAM, NOR and NAND flash memory chips, serial data devices, chipsets, microprocessors, and microcontrollers. It sells its products to DRAM, flash memory devices, microprocessor, chipset, and other system on chip devices manufacturers primarily through its direct sales force, distributors, and independent sales representatives. The company operates in Japan, North America, the Asia Pacific, and Europe. FormFactor, Inc. was founded in 1993 and is headquartered in Livermore, California.

CROCS INC (NASDAQ:CROX) - Crocs, Inc. and its subsidiaries engage in the design, development, manufacture, marketing, and distribution of footwear for men, women, and children. The company primarily offers casual and athletic shoes, and shoe charms. It also designs and sells a range of footwear and accessories that utilize its proprietary closed cell-resin, called Croslite. In addition, the company offers a line of apparel for boys and girls; men featuring Croslite material; and accessories, including snap-on charms and messenger bags. Further, it provides leather and ethylene vinyl acetate based sandals principally for the beach, adventure, and action sports markets. The company sells its products through domestic and international retailers and distributors, as well as directly to end-user consumers through its Web stores, company-operated retail stores, outlets, and kiosks primarily under the Crocs, Jibbitz, Ocean Minded, and YOU by Crocs brand names. As of December 31, 2009, it operated 170 domestic and international retail kiosks located in malls and other high foot traffic areas; 84 domestic and international retail stores; 63 domestic and international outlet stores; and 23 Web stores. Crocs, Inc. operates in the Americas, Europe, and Asia. The company was formerly known as Western Brands, LLC and changed its name to Crocs, Inc. in January 2005. Crocs, Inc. was founded in 1999 and is based in Niwot, Colorado.

HOUSTON WIRE & CABLE CO (NASDAQ:HWCC) - Houston Wire & Cable Co. distributes specialty wire and cable products in the U.S., including continuous and interlocked armor cables, control and power cables, electronic wire and cables, flexible and portable cords, instrumentation and thermocouple cables, lead and high-temperature cables, medium-voltage cables, and premise and category wire and cables. The company also offers private-brand products including LifeGuard low-smoke and zero-halogen cable, DataGuard engineered cables, and Houwire low-voltage cables. It serves industries including communications, energy, engineering and construction, general manufacturing, infrastructure, petrochemical, transportation, utility, and wastewater treatment. The company was founded in 1975 as hwc Holding Corp. and changed its name to Houston Wire & Cable in 2006. It is headquartered in Houston.

OSIRIS THERAPEUTICS INC (NASDAQ:OSIR) - Osiris Therapeutics, Inc., a stem cell therapeutic company, focuses on developing and marketing products to treat medical conditions in the inflammatory, orthopedic, and cardiovascular areas in the United States and internationally. Its lead biologic drug candidate includes Prochymal, which is in Phase 3 clinical trials for the treatment of acute and steroid refractory graft versus host disease (GvHD) and Crohn's disease, as well as for the repair of gastrointestinal injury resulting from radiation exposure. The company is also developing its Prochymal drug candidate for the repair of heart tissue following a heart attack, and for the protection of pancreatic islet cells in patients with type 1 diabetes. In addition, it is developing Chondrogen, a biologic drug candidate for the treatment of osteoarthritis and the reduction of pain in the knee. Additionally, the company focuses on developing biologic products for use in surgical procedures. The company has collaboration agreements with Genzyme Corporation for the development and commercialization of Prochymal and Chondrogen; Juvenile Diabetes Research Foundation for developing Prochymal as a treatment for the preservation of insulin production in patients with newly diagnosed type 1 diabetes; and JCR Pharmaceuticals Co., Ltd. for the distribution of Prochymal for GvHD in Japan. Osiris Therapeutics was founded in 1992 and is headquartered in Columbia, Maryland.

URANERZ ENERGY CORP (AMEX:URZ) - Uranerz Energy Corporation, an exploration stage company, engages in the acquisition, exploitation, and development of uranium properties. The company principally focuses on the exploration of its properties in the Powder River Basin area of Wyoming encompassing approximately 119,312 acres, as well as owns interests in properties located in the Great Divide Basin area of Wyoming, Texas and in Saskatchewan, Canada. The company was formerly known as Carleton Ventures Corp. and changed its name to Uranerz Energy Corporation in July 2005. Uranerz Energy Corporation was founded in 1999 and is based in Casper, Wyoming.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net